Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors

ABSTRACT: The purpose of this study is to determine the recommended Phase II dose of nilotinib when used in combination with cetuximab in the treatment of patients with recurrent and/or metastatic Kras wildtype colorectal cancer or squamous cell carcinoma of the head and neck.

DISEASE(S): Colorectal Cancer,Head And Neck Neoplasms,Head And Neck Cancer

PROVIDER: 2146162 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Project description:To determine the differential expression of KRAS-variant HNSCC (head and neck squamous cell carcinoma) cell lines.

2014-10-02 | GSE36110 | GEO

A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Project description:To determine the differential expression of KRAS-variant HNSCC (head and neck squamous cell carcinoma) cell lines. Total RNA collected from a panel of HNSCC cell lines.

2014-10-02 | E-GEOD-36110 | biostudies-arrayexpress

Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins

Project description:Unraveling the underlying mechanisms of cetuximab resistance in head and neck squamous cell carcinoma (HNSCC) is of major importance as many tumors remain non-responsive or become resistant. Out microarray results suggest that resistant cells still exhibit RAS-MAPK pathway signaling contributing to drug resistance, as witnessed by low expression of DUSP 5 and DUSP6, negative regulators of ERK1/2, and increased expression of AURKB, a key regulator of mitosis. Therefore, interrupting the RAS-MAPK pathway by an ERK1/2 inhibitor (apigenin) or an AURKB inhibitor (barasertib) might be a new strategy for overcoming cetuximab resistance in HNSCC 4 head and neck squamous cell carcinoma (HNSCC) cell lines were treated with either 15 nM cetuximab or PBS during 13 hours. For each cell line, differential gene expression was assessed between cetuximab and PBS treatments.

2014-09-18 | E-GEOD-61495 | biostudies-arrayexpress

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

Project description:This is a Phase 1b/2, open-label multicenter study evaluating NKTR-255 as a monotherapy and together with cetuximab in patients with head and neck squamous cell carcinoma (HNSCC), colorectal carcinoma (CRC), cutaneous squamous cell carcinoma (cSCC), anal cell carcinoma (ASCC) and cervical cancer. The recommended phase 2 dose of NKTR-255, determined in the dose escalation phase (Phase 1b), will be used to treat patients in Phase 2 of this study.

| 2356733 | ecrin-mdr-crc

Molecular subtypes of head and neck cancer – Prognostic impact and correlations with morphological characteristics

Project description:Aim Treatment options for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) are limited. Therefore, prognostic and predictive biomarkers for the application of personalized therapies are urgently needed.

2023-06-01 | GSE212070 | GEO

Gene expression profiles of head and neck squamous cell carcinoma

Project description:Sage performed on microdissection of Head and Neck tumor, and Head and Neck normal tissue comparative analysis of gene expression profiles of head and neck squamous cell carcinoma and Head and Neck normal tissue

2008-09-30 | E-GEOD-11986 | biostudies-arrayexpress

MethylationEPIC array from fresh oral and oropharyngeal tissue samples from head and neck squamous cell carcinoma patients, tissue samples from potentially premalignant oral lesions and fresh tonsil tissue samples from control patients

Project description:This data was used to detect good biomarkers for head and neck squamous cell carcinoma and was integrated with transcriptome and miRNome data aiming to elucidate role of epigenetics on gene expression in head and neck squamous cell carcinoma.

2024-04-22 | E-MTAB-13954 | biostudies-arrayexpress

Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapy

Project description:VCN-01 is a hyaluronidase-expressing oncolytic adenovirus that increases immune checkpoint antibody tumor uptake in mice. VCN-01 was evaluated with durvalumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients refractory to anti-PD-(L)1

2026-06-03 | GSE333537 | GEO

Gene expression analysis of head and neck squamous cell carcinoma cell lines and a control normal oral epithelial cell line

Project description:Microarrays were used to examine gene expression differences between human head and neck squamous cell carcinoma cell lines (FaDu, UTSCC8, UTSCC42a) grown in culture in comparison to a normal oral epithelial cell line. Gene expression data was integrated with global protein expression of head and neck squamous cell carcinoma cell lines and conditioned media to identify secreted protein markers up-regulated at the mRNA level in cancer cells versus the normal cell line. Total RNA obtained from head and neck squamous cell carcinoma cell lines and a normal oral epithelial cell line

2012-08-28 | E-GEOD-40185 | biostudies-arrayexpress

Transcriptomic characterization of heterogeneity in paired primary and recurrent HNSCC tumors

Project description:Despite aggressive multi-modal treatment, advanced head and neck squamous cell carcinoma (HNSCC) patients are at high risk of recurrence. n=19 different selected areas of matched pairs (n=3) of primary/recurrent tumor specimens were subjected to RNA sequencing. Transcriptional subtyping (classical/CL, basal/BA, inflamed-mesenchymal/IMS) in matched primary and recurrent HNSCC specimens revealed heterogeneity.

2022-04-08 | GSE186461 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data